S-5022-119
Read twice and referred to the Committee on Finance.
Sponsored by Cory Booker (D-NJ)
What it does
This bill would remove cannabis from Schedule I of the Controlled Substances Act, effectively ending federal criminalization. It would transfer regulatory authority over cannabis from the DEA to the FDA (for public health) and a renamed Alcohol, Tobacco, and Cannabis Tax and Trade Bureau (for taxation and trade). The bill would also require expungement of prior federal cannabis convictions, mandate release of individuals currently incarcerated solely for federal cannabis offenses, establish a federal excise tax on cannabis products with revenue directed to an Opportunity Trust Fund, and preserve each state's authority to set its own cannabis laws while prohibiting states from blocking interstate cannabis transportation.
Who benefits
Individuals currently incarcerated or on supervised release for federal cannabis-only offenses, who would be released and have convictions vacated. People with prior federal cannabis convictions who face collateral consequences in employment, housing, and immigration. Unauthorized immigrants previously deported or facing deportation for cannabis offenses. Legal cannabis businesses (417,000+ jobs) that would gain access to banking, SBA loans, and federal financial services. Minority and tribal small business owners who face disproportionate barriers to cannabis industry entry. Medical researchers who would gain expanded access to cannabis for clinical studies, including VA researchers studying veterans with chronic pain and PTSD. States that have already legalized cannabis, whose laws would no longer conflict with federal law. Consumers in legal-cannabis states who would gain federal consumer protections. Public health agencies receiving new funding for surveillance, prevention, and underage-use programs.
Who is hurt
Law enforcement agencies and prosecutors who would lose federal cannabis enforcement authority and associated funding streams. Private prison operators and related industries that may see reduced federal inmate populations. Drug testing companies and employers in safety-sensitive industries, though the bill preserves testing authority for national security and public safety positions. Cannabis businesses in states that currently prohibit cannabis, which could face increased competitive pressure if interstate commerce eventually flows. Anti-drug advocacy organizations whose policy positions would be undermined by federal legitimization. Alcohol and tobacco industries that would face a new federally regulated competitor. Communities in states without legalization that could see increased cross-border diversion despite the bill's anti-diversion provisions. Individuals who believe broader cannabis availability will increase youth use or public health harms, despite the bill's prevention funding.
Supporters argue
Supporters argue that federal cannabis prohibition has failed on its own terms while producing severe racial disparities: Black Americans are nearly four times more likely to be arrested for cannabis possession than white Americans despite equal usage rates, and Black men receive drug sentences averaging 13.1% longer than white men for the same conduct. They contend that 49 states have already reformed their cannabis laws, the FDA itself has identified credible scientific support for medical cannabis use, and continued federal criminalization costs taxpayers approximately $3.6 billion annually in enforcement while generating zero tax revenue from a $33.6 billion legal market. Supporters further argue the bill addresses the contradiction between federal law and the reality on the ground in most of the country, while building in robust public health safeguards — including underage-use prevention grants, impaired driving research, and expanded biomedical research funding.
Opponents argue
Opponents argue that federal descheduling would permanently entrench a commercial cannabis industry before science has resolved serious public health questions, including cannabis's links to psychosis, adolescent cognitive development, and cardiovascular risk — concerns the bill's own research mandates implicitly acknowledge are unresolved. They contend that state-level legalization has already been associated with increased youth use in some studies, and that removing the federal scheduling backstop eliminates a meaningful deterrent while making it harder to reverse course if harms materialize. Opponents further argue that the bill's expungement and mandatory release provisions, while framed as restorative justice, bypass normal judicial review and could release individuals whose cannabis convictions were part of broader criminal conduct, and that the interstate transportation preemption of state law undermines the federalism principles the bill claims to protect.
Constitutional context
Congress's authority to schedule and deschedule controlled substances rests on the Commerce Clause; Gonzales v. Raich (2005) held that federal prohibition of even locally grown cannabis was within that power, meaning Congress has clear authority to remove that prohibition as well. The bill's mandatory expungement and release provisions implicate the Fifth Amendment's Due Process Clause and the separation of powers, as Congress would be directing courts to vacate convictions and ordering the executive branch to release prisoners on a fixed timeline, which may raise questions about judicial independence and executive clemency authority.
Checks and balances
The executive branch (FDA and the renamed TTB) gains significant new regulatory authority over a major commercial sector, checked by congressional oversight, judicial review of agency rules under the post-Loper Bright independent-judgment standard, and preserved state police powers over cannabis within their borders.
Historical precedent
The 21st Amendment (1933) repealed federal alcohol prohibition and returned regulatory authority to states, providing the closest structural analogue; this bill explicitly models portions of its regulatory framework on the Federal Alcohol Administration Act.